STOCK TITAN
  1. Home
  2. News
  3. EXAS

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.

In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.

The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.

  • Headquartered in Madison, Wisconsin
  • Specializes in cancer screening and diagnostic tests
  • Flagship product: Cologuard, a noninvasive colorectal cancer screening test
  • Precision oncology products: Oncotype DX and OncoExTra
  • Active development of liquid biopsy tests
  • Exclusive intellectual property rights protecting screening technology

For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.

News

Exact Sciences Schedules First Quarter 2024 Earnings Call

Rhea-AI Summary
Exact Sciences Corp. (EXAS) to release its first quarter 2024 financial results on May 8, 2024. The company will host a webcast and conference call to discuss financial results and business progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
earnings
-
News

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

Rhea-AI Summary
Exact Sciences partners with Mayo Clinic to offer comprehensive genomic profiling and hereditary cancer tests, enhancing cancer research and patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
News

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Rhea-AI Summary
Exact Sciences Corp. collaborates with Mayo Clinic to develop a non-endoscopic screening tool for esophageal adenocarcinoma and its precursors, showing high sensitivity and specificity in detecting early stages of the cancer. The test aims to address the critical need for screening in high-risk populations, with potential to revolutionize esophageal cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
News

Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner

Rhea-AI Summary
Exact Sciences Corp. (EXAS) receives the 2024 Gallup Exceptional Workplace Award for its engaged workplace culture, highlighting dedication to teamwork, well-being, and professional growth. The company's employee engagement ratio surpasses global averages, emphasizing its commitment to eradicating cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
News

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

Rhea-AI Summary
Exact Sciences Corp. announces the online publication of the BLUE-C study results in The New England Journal of Medicine, showcasing the performance of their next-generation multitarget stool DNA test, Cologuard Plus, for colorectal cancer screening. The study demonstrated 94% sensitivity for CRC at 91% specificity, outperforming the fecal immunochemical test. Cologuard Plus aims to reduce unnecessary follow-up colonoscopies and is set to be available in 2025 pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
-
News

Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer

Rhea-AI Summary
Exact Sciences Corp. collaborates with The Blue Hat Foundation to launch 'Box Out Colon Cancer' campaign with Jamal Mashburn, promoting colorectal cancer screening and prevention during Colorectal Cancer Awareness Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.22%
Tags
none
News

Exact Sciences to Participate in March Investor Conference

Rhea-AI Summary
Exact Sciences Corp. (EXAS) to participate in TD Cowen 44th Annual Health Care Conference with a fireside chat on March 4, 2024. Investors invited to join via webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences
-
News

Exact Sciences Announces Fourth Quarter 2023 Results

Rhea-AI Summary
Exact Sciences Corp. reports record revenue, positive free cash flow, and expects 2024 revenue of $2.810-2.850 billion. The fourth quarter and 2023 highlights include total revenue of $647 million, a 17% increase, with Screening revenue at $487 million and Precision Oncology revenue at $160 million. The company's financial results showcase growth in both revenue and cash flow, reflecting a strong performance in cancer screening and diagnostic tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
earnings
-
News

Exact Sciences Schedules Fourth Quarter 2023 Earnings Call

Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) plans to release its fourth quarter 2023 financial results on February 21, 2024, followed by a webcast and conference call to discuss financial results and business progress. The webcast and call will be open to all interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
earnings
News

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, and submits next-generation Cologuard to FDA. The company also announces Chief Financial Officer succession plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
earnings

FAQ

What is the current stock price of Exact Sciences (EXAS)?

The current stock price of Exact Sciences (EXAS) is $54.79 as of January 22, 2025.

What is the market cap of Exact Sciences (EXAS)?

The market cap of Exact Sciences (EXAS) is approximately 9.9B.

What is Exact Sciences Corp's main business?

Exact Sciences Corp specializes in molecular diagnostics, focusing on innovative cancer screening and diagnostic test products.

What is Cologuard?

Cologuard is a noninvasive stool-based DNA test designed to screen for colorectal cancer, integrated into major colorectal cancer screening guidelines.

Where is Exact Sciences Corp headquartered?

The company is headquartered in Madison, Wisconsin.

What are Oncotype DX and OncoExTra?

Oncotype DX is a suite of tissue-based genomic tests for cancer recurrence risk and chemotherapy benefit; OncoExTra is a liquid biopsy for comprehensive genomic profiling.

Is Exact Sciences developing any new tests?

Yes, the company is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

What is the significance of Exact Sciences' intellectual property?

Exact Sciences has exclusive intellectual property rights protecting its noninvasive molecular screening technology, reinforcing its market leadership.

Are Exact Sciences' products used internationally?

Yes, Exact Sciences provides cancer screening and diagnostic test products both in the United States and internationally.

How does Cologuard work?

Cologuard works by analyzing stool samples for DNA markers and blood that could indicate the presence of colorectal cancer or precancerous lesions.

What is the purpose of Oncotype DX tests?

Oncotype DX tests aim to estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy in breast and colon cancer patients.

Where can more information about Cologuard be found?

More information about Cologuard can be found at cologuardtest.com.
Stock EXAS logo
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

#885 Ranked by Market Cap
N/A Ranked by Dividends

EXAS Stock Data

9.90B
182.39M
1.01%
101.55%
6.05%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
MADISON